News | February 09, 2009

SNM Workshop Underscores Imaging’s Value in Drug Development

February 9, 2009 - Presenters at the workshop stressed the need for the correct imaging biomarker available to accelerate the completion of clinical trials, as well as imaging standardization, consistent manufacturing practices and regulatory considerations, at The SNM Clinical Trials Network Community Workshop held on Feb. 8, 2009, in Clearwater, FL.
Speakers from the field of molecular imaging, regulatory agencies and pharmaceutical developers focused on the critical need to increase the use of imaging biomarkers in clinical trials and called for immediate action.

"The time to develop new imaging biomarkers is now," said Jeff Evelhoch, vice president of imaging at Merck. "We must come together as a community to make this happen, working together to facilitate the regulatory process."

Experts in oncology, cardiology, dementia and cell therapeutics discussed the important role that imaging biomarkers - indicators of a particular disease state or a particular state of an organism - can play in drug development studies. Other speakers addressed the challenges that researchers and imagers currently face in harmonizing imaging results between different locations in a multicenter trial.

“SNM’s Clinical Trials Network was conceived just for this reason: to create a standardized protocol across multiple sites in the U.S. and internationally in order to expedite the creation of new biomarkers for use in clinical trials,” said Michael Graham, M.D., Ph.D., president-elect of SNM and a chair of SNM’s Clinical Trials Network. “We are currently registering potential imaging sites, assessing their ability to participate in the Clinical Trials Network, and looking forward to announcing the first clinical trial in late 2009.”

“The role of medical imaging in clinical trials is rapidly increasing due to the ability to provide patient assessment and early drug trial results,” said Gustav K. von Schulthess, M.D., Ph.D., professor and director of nuclear medicine, University Hospital, Zurich, Switzerland, who was the keynote speaker at the workshop. “SNM’s Clinical Trials Network is expected to assist greatly by creating and enforcing standards among multiple trial sites, which, in the end, will benefit imagers, pharmaceutical manufacturers and patients.”

Pharmaceutical developer representative Diane Jorkasky, M.D., FACP, and former vice president of Global Clinical Research Operations at Pfizer, helped the audience understand the industry perspective on the use of medical scanning in drug development, how different therapeutic areas view the value of that scanning and how “go/no-go” decisions are used when employing such imaging.

"Only through partnerships comprising researchers, pharmaceutical developers and government will we be able to achieve novel approaches necessary to establishing successful clinical trials," she said. According to Dr. Jorkasky, one of the key attributes of a standardized trials protocol is that imagers and pharmaceutical developers will have insight earlier whether a drug under development shows potential for truly helping patients who can benefit from molecular imaging pharmaceuticals.

Wendy Sanhai, Ph.D., senior scientific advisor, Immediate Office of the Commissioner, U.S. Food and Drug Administration, closed the day's presentations by acknowledging the critical role of medical imaging agents in early diagnosis, as well as patient care and monitoring disease progression. "Medical imaging techniques can provide real-time feedback on drug effectiveness and separate those patients who respond from those who do not and thus allow successful clinical decisions for the most effective treatment," she said.

Dr. Sanhai described clinical studies that incorporate imaging and that are currently underway in collaboration with multiple stakeholders. Her presentation provided updates on studies being facilitated within the Biomarker Consortium--a public-private research partnership of the Foundation for the National Institutes of Health--as well as efforts underway at FDA to facilitate biomarker development.

For more information: www.snm.org/clinicaltrials

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init